NASDAQ:SAVAW

Cassava Sciences (SAVAW) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.03
▼
$0.03
52-Week Range: $0.02
▼
$11.02

Volume: N/A
Average Volume: 474,310 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Short Interest Trends

Get Cassava Sciences alerts:

Ad MarketBeat

We just added a $300 account credit to your MarketBeat subscription

MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.

Start Your Risk-Free Trial Here

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Ad MarketBeat

We just added a $300 account credit to your MarketBeat subscription

Start Your Risk-Free Trial Here

SAVAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive SAVAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: Pharmaceutical Products
Current Symbol: NASDAQ:SAVAW
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: 512-501-2444
Fax: N/A
Employees: 30
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: No Data
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Remi Barbier (Age 64)
Founder, Chairman, President & CEO
Comp: $1.2M
Mr. Eric J. Schoen (Age 56)
Chief Financial Officer
Comp: $460k
Mr. R. Christopher Cook (Age 60)
Senior VP, Company Secretary & General Counsel
Comp: $425k
Dr. James W. Kupiec M.D. (Age 71)
Chief Medical Officer
Comp: $435k
Dr. George Thornton Ph.D.
Senior Vice President of Technology
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience